SG&A at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's SG&A?
- Ionis Pharmaceuticals (IONS) reported SG&A of $150.36M in Q1 2026.
- How has Ionis Pharmaceuticals's SG&A changed year-over-year?
- Ionis Pharmaceuticals's SG&A increased by 97.2% year-over-year, from $76.25M to $150.36M.
- What is the long-term trend for Ionis Pharmaceuticals's SG&A?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's SG&A has grown at a 20.6% compound annual growth rate (CAGR), from $186.35M to $393.87M.
- What does SG&A mean?
- The overhead costs of running the business and selling products.
- How do you interpret SG&A?
- Rising SG&A without proportional revenue growth may indicate inefficient scaling or excessive administrative overhead.
- How does SG&A compare across companies?
- Varies by company maturity; early-stage biotech firms often have lower SG&A until they begin commercializing products.